Berzosertib
Berzosertib (M6620) is a first-in-class selective ATR kinase inhibitor that abrogates replication stress responses by blocking ATR-mediated CHK1 activation. Cancer cells with elevated replication stress (RAS mutations, CCNE1 amplification, ATM loss) are particularly sensitised. In combination with DNA-damaging agents, it enhances anti-tumour activity across multiple Phase I/II trials.
Description
Scientific Overview: Berzosertib (M6620) is a first-in-class selective ATR kinase inhibitor that abrogates replication stress responses by blocking ATR-mediated CHK1 activation. Cancer cells with elevated replication stress (RAS mutations, CCNE1 amplification, ATM loss) are particularly sensitised. In combination with DNA-damaging agents, it enhances anti-tumour activity across multiple Phase I/II trials.
Mechanism of Action: ATR Kinase Inhibitor
Purity: ≥99% | Molecular Formula: C22H16N6O3
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | ATR Kinase Inhibitor |
|---|---|
| Purity | ≥99% |
| Molecular Formula | C22H16N6O3 |
| CAS Number | 1802220-02-5 |
